Development of latent tuberculosis and adverse effects with isoniazid during biologist therapy´s in Crohn´s Disease

  • María Alejandra Arriola Facultad de Medicina, Universidad de la República
  • Lucía Secondo Facultad de Medicina, Universidad de la República
  • Karla Avendaño Facultad de Medicina, Universidad de la República
  • Beatriz Iade Facultad de Medicina, Universidad de la República
Keywords: Anti-tumor necrosis factor alfa, isoniazid, inflammatory bowel disease, tuberculosis

Abstract

Anti-tumor necrosis factor alfa drugs are responsible for blocking one of the cytoquines implicated on inflammatory bowel disease pathogenesis. Its use has been linked to an increase in tuberculosis cases which is why screening before starting treatment is mandatory. Latent tuberculosis is treated with isoniazid as chemoprophylaxis although its use may provoke adverse effects. A case is presented of a patient with skin adverse reaction due to the use of isoniazid.

Downloads

Download data is not yet available.

Author Biographies

María Alejandra Arriola, Facultad de Medicina, Universidad de la República

Hospital de Clínicas, Clínica de Gastroenterología, Prof. Dr. Henry Cohen

Lucía Secondo, Facultad de Medicina, Universidad de la República

Hospital de Clínicas, Clínica de Gastroenterología, Prof. Dr. Henry Cohen

Karla Avendaño, Facultad de Medicina, Universidad de la República

Hospital de Clínicas, Clínica de Gastroenterología, Prof. Dr. Henry Cohen

Beatriz Iade, Facultad de Medicina, Universidad de la República

Hospital de Clínicas, Clínica de Gastroenterología, Prof. Dr. Henry Cohen

Published
2017-10-12
How to Cite
Arriola, M. A., Secondo, L., Avendaño, K., & Iade, B. (2017). Development of latent tuberculosis and adverse effects with isoniazid during biologist therapy´s in Crohn´s Disease. Anales De La Facultad De Medicina, 4(2), 78-83. Retrieved from https://revistas.udelar.edu.uy/OJS/index.php/anfamed/article/view/202
Section
Casos clínicos